Background: The role of the high affinity IgE receptor, FceRI, in IgE-mediated immune responses of the gastrointestinal (GI) mucosa is poorly understood. Currently, a detailed characterization of FceRI expression throughout the human gut is lacking. The aim of this study was to define the expression pattern of FceRI in the GI tract.
Introduction
The gastrointestinal (GI) mucosa is a large interface area for pathogens and environmental antigens and, therefore, is under constant surveillance of the immune system. Immunoglobulin (Ig) receptors are gatekeepers of host defense at mucosal surfaces; they shuttle Ig-antigen complexes across the healthy epithelium and activate protective immune responses. Misguided immune responses, however, can lead to inflammation of the gut or other allergic reactions towards harmless allergens. IgE and its cellular receptors are key players in allergic reactions and parasite defense. Humans express three IgE-receptors, the high affinity IgEreceptor, FceRI, and two low-affinity IgE receptors, FceRII (or CD23), and e-binding protein eBP (or galectin 3) [1] . In the human GI mucosa, the expression of the low affinity IgE receptors is well documented; CD23 is expressed on intestinal epithelial cells and functions as an antigen-sampling protein for IgE-antigen complexes, implying that CD23 plays a role in food allergy [2, 3, 4, 5, 6, 7] . Galectin 3 has been shown to be downregulated during intestinal inflammation and is associated with colon cancer progression [8, 9, 10, 11] . There is little data, however, on the expression profile of the high affinity receptor FceRI in the gastrointestinal mucosa.
FceRI is a multimeric receptor of the immunoglobulin receptor superfamily and binds the Fc-part of IgE with its immunoglobulin domain-containing a-chain. Allergen-mediated crosslinking of IgE-FceRI complexes on the surface of blood and tissue cells then triggers the allergic cascade via the receptor's signaling subunits, FceRIb and FceRIc [12] . Human FceRI is expressed in a tretrameric form (FceRIabc 2 ) on the surface of mast cells and basophils, and in a trimeric form (FceRIac 2 ) on eosinophils, macrophages, and dendritic cells (DCs) [1] . In peripheral blood, the majority of FceRI-expressing cells carry IgE [13, 14] . Since binding of IgE to FceRIa stabilizes the IgE-receptor complex, cell surface expression of FceRI on peripheral blood cells has been shown to tightly correlate with serum IgE levels as well as cellbound IgE [15, 16, 17] .
In the GI tract, FceRI-expressing DCs of the Langerhans cell type have been described in the oral mucosa [18] and in the esophageal epithelium of children with gastroesophageal reflux and Eosinophilic Esophagitis (EoE), an allergic condition of the upper GI tract [19] . FceRI is the only IgE receptor that is expressed in the esophagus [19] . Untersmayr et al. detected FceRI-positive epithelial cells in the terminal ileum and the colon of colon cancer patients and patients with inflammatory conditions of the gut [20] . Previously, IgE-loaded mast cells have been described in the intestinal mucosa of food allergic-as well as healthy individuals [21, 22] .
A detailed analysis of mucosal FceRI expression throughout the GI tract is currently not available. The aim of the present study, therefore, was to characterize the expression pattern of FceRI throughout the GI tract and to investigate the impact of serum IgE levels and mucosal inflammation on FceRI expression levels.
Results

Study Population
We investigated mucosal specimens from a total of 34 pediatric patients (15 girls, 19 boys, median age at time of endoscopy 12.4 years). Patients had a diagnosis of gastritis/esophagitis (n = 10), celiac disease (n = 10), or inflammatory bowel disease (IBD) (n = 9). Biopsies of 5 patients did not show any mucosal pathology and served as normal controls. Total serum IgE was measured at the time of endoscopy. Fifteen patients had elevated serum IgE levels (gastritis/reflux n = 5, celiac disease n = 5, IBD n = 4, normal n = 1). In 19 patients, IgE levels were within the normal range. Patients' characteristics are summarized in Table 1 . Children were not routinely tested for the presence of intestinal parasites or helminths, but the expected prevalence for such infections is negligible in a Central European country.
Histological Detection of FceRI in the GI Mucosa
We conducted immunohistochemistry staining of snap-frozen mucosal biopsies from all sections of the GI tract accessible by endoscopy. FceRIa was frequently found on cells infiltrating the mucosa of the upper GI tract (esophagus, Figure 1A and F, stomach Figure 1B and G, and duodenum, Figure 1C and H). Specimens from the lower GI tract (terminal ileum, colon, and rectum) showed only scattered FceRI positive cells ( Figure 1D and I). We recently identified Langerhans cells and mast cells as the main bearers of FceRI in the esophageal epithelium by immunohistochemistry double-staining [19] . Here, double-immunofluorescence staining of snap-frozen esophageal specimens confirmed that FceRI was expressed on c-kit-positive intraepithelial mast cells ( Figure 2 ) and CD1a-positive Langerhans cells (Figure 3 Figure 4A , middle panel). In line with its function as a common signaling chain for several Fc receptors [23] , Fc-receptor-c mRNA was present in most specimens from all sections of the gut (right panel). FceRIa mRNA levels were highest in the esophagus and decreased along the GI tract ( Figure 4B , left panel). FceRIb mRNAexpression peaked in the gastric mucosa (middle panel). Esophageal specimens were low in FceRIc transcripts compared to the stomach, terminal ileum, colon, and rectum (right panel, MannWhitney-U test). This data demonstrate that, as measured at the mRNA level, the FceRIa and b subunits are robustly expressed in the proximal parts of the GI tract and their expression levels decrease towards the distal intestine, while the common Fcreceptor-c chain is expressed throughout the entire GI mucosa.
Tissue mRNA Levels of FceRIa do not Correlate with Serum IgE Levels
IgE-binding to FceRIa stabilizes the receptor complex at the cell surface [15] . It has also been suggested that IgE-binding promotes FceRIa transcription [24] . Therefore, we investigated the correlation of serum IgE levels with tissue mRNA levels of the three FceRI-subunits. In specimens from the esophagus, the stomach and the duodenum with detectable FceRIa-, b-, or cmRNA expression, no correlations between serum IgE and any of the receptor subunits were found ( Figure normal IgE patients in the entire gut ( Figure 5B , right panel, Mann-Whitney-U test, respectively). The low frequency of FceRIa-and b-mRNA positive specimens did not allow for comparative analysis in the large intestine. Our experiments permit us to conclude that our findings regarding the correlation of serum IgE levels and FceRI expression in peripheral blood [13] cannot be extended to the GI mucosa.
FceRI mRNA Expression Levels are Modulated by Inflammation of the GI Tract
We have previously shown that FceRI-bearing immune cells infiltrate the esophageal mucosa of children with reflux esophagitis and EoE, two inflammatory conditions of the esophagus [19] . We, therefore, hypothesized that the mucosa of patients with inflammatory conditions of the gut should express high levels of FceRI transcripts due to the influx of inflammatory immune cells. In support of this hypothesis, we found that some gastritis/ esophagitis patients in our study showed higher FceRIa mRNA levels in the esophagus than celiac disease-and IBD-patients or normal controls ( Figure 6A ). We note that the specimens that contained FceRIa mRNA in the terminal ileum, the colon, and the rectum were obtained from two IBD patients, while one colon biopsy from a normal control patient was also positive for FceRIa mRNA. In the gastric mucosa, FceRIb mRNA levels appeared to be higher in diseased children than in normal controls ( Figure 6B ). These differences, however, were not statistically significant (measured using a Kruskal-Wallis test). A statistically significant difference between patient subgroups was found for the FceRIc expression levels in gastric specimens ( Figure 6C , p = 0.031, Kruskal-Wallis test). Group-by-group comparison did not reveal statistically significant differences between the respective patient subgroups though (Mann-Whitney-U test with Bonferroni-Holm correction for multiple testing). In summary, our data suggest that inflammatory infiltration of the GI mucosa may be associated with an increase in FceRI tissue mRNA expression, although the small patient cohort did not permit statistically significant results.
Discussion
We show here that the high affinity IgE receptor, FceRI, is highly expressed on cells infiltrating the mucosa of the esophagus, the stomach, and the duodenum, and shows a low level of expression in more distal parts of the GI tract. Accordingly, tissue mRNA of all three FceRI subunits was detected in the intestinal mucosa. FceRIa-, b-, and c-mRNA levels did not correlate with total serum IgE, but were modulated by gastrointestinal inflammation.
FceRIa mRNA was most abundant in the esophageal mucosa and could be detected in every patient. FceRIb mRNA levels, on the other hand, were rather low in the esophagus and peaked in the gastric mucosa. This could reflect the predominance of cells expressing the trimeric receptor isoform, such as dendritic cells and eosinophils, in the esophagus. In the stomach, cells bearing the tetrameric FceRIabc2, such as mast cells and basophils, could be the main FceRI-expressing population. This interpretation is supported by previous studies showing that the gastric mucosa is particularly rich in mast cells [25, 26, 27] , whereas in the esophagus eosinophils and dendritic cells are the major FceRI-positive populations [19] . The common Fc-c-chain mRNA was abundantly found in almost all biopsies. The increasing levels of the Fcc-chain along the GI system most likely reflect the physiologic increase in Fc-receptor-bearing mucosal immune cells even in healthy subjects [28, 29] .
The binding of IgE, the natural ligand to FceRI, increases FceRI expression on peripheral blood cells and Langerhans cells [13, 30, 31] by stabilizing the receptor on the cell surface [15] . It has been suggested that IgE also upregulates FceRIa transcription, although this hypothesis has been disputed [24, 32] . We did not find any significant correlation between mucosal FceRIa-, -b-, orc-mRNA expression levels and serum IgE in any part of the GI tract. Our data thus support earlier observations that FceRI expression is likely regulated on the protein rather than the mRNA level [32] .
Total IgE values in mixed-age pediatric populations are not directly comparable due to differing age-related normal ranges. To overcome this problem, absolute IgE levels are commonly converted into age-normalized z-values as published by Kjellman et al. [33] . We did not detect a significant correlation when we used z-units instead of absolute IgE values either (data not shown). Nonetheless, it is possible that the mucosal immune system is more autonomous than previously assumed. Vicario et al. recently discovered local isotype class-switching to IgE and IgE production in the esophageal mucosa of EoE patients, regardless of their atopic status [34] . Local IgE production might also boost mucosal FceRI-expression, independent of systemic serum IgE levels.
We observed that mucosal inflammation was associated with FceRIa mRNA levels, based on our finding that patients with a histopathological diagnosis of esophagitis displayed the highest FceRIa mRNA expression. The highest copy numbers of esophageal FceRIa mRNA were found in two celiac disease patients. According to routine pathology records, these two patients also had intraepithelial inflammatory infiltrates in the esophagus. Therefore, high FceRIa mRNA expression could be a surrogate for invading FceRIa-positive inflammatory cells. Further supporting this argument, previous studies identified intraepithelial Langerhans cells and mast cells in the inflamed esophageal mucosa of children with EoE and reflux esophagitis as the main cellular sources of FceRI [19, 35] . Other studies described the infiltration of IgE-loaded mast cells in the duodenal mucosa of patients with food-related diarrhea [21] . In line with these previous findings, we also identified intraepithelial mucosal mast cells and Langerhans cells as the FceRI-expressing cells. With respect to the distal sections of the intestine, Untersmayr et al. recently identified epithelial FceRIa expression in Paneth cells in small intestinal crypts and colon epithelium in colon cancer patients, and in patients with various gastrointestinal inflammatory conditions. Samples from healthy controls were negative for the receptor in this study. The authors, therefore, proposed a role for mucosal FceRI expression in gastrointestinal pathology [20] . Our data support Untersmayr's data as two out of nine IBD patients were positive for mucosal FceRIa mRNA in the terminal ileum and the large intestine.
The role of the low affinity IgE receptor, CD23, in transepithelial transfer of IgE-allergen complexes is well established [5] . FceRI, in contrast, does not seem to be involved in antigen-shuttling, as it is localized to infiltrating cells rather than epithelial cells. It is tempting to speculate that FceRI may function as an antigen uptake-receptor on mucosal DCs with the capacity to sample allergen from the gastrointestinal lumen via FceRI-bound specific IgE, as has been shown in mouse models [36, 37, 38] .
In summary, we show here that FceRI is robustly expressed in the upper GI mucosa of pediatric patients at steady state. Inflammatory conditions, independent of the underlying pathology, lead to increased FceRI tissue mRNA expression. In conclusion, our data define the upper GI tract as the main site for IgE-mediated immune activation via FceRI. Once the immune homeostasis is disturbed by an inflammatory condition such as IBD, the lower GI tract becomes susceptible to IgE-mediated immune reactions as well. The fact that we see tissue FceRIa mRNA regulation by inflammatory conditions independent of IgE-mediated disorders indicates that this receptor might also play a role in pathologies other than allergies.
Materials and Methods
Ethics Statement
The study protocol was approved by the Ethic's Committee of the Medical University of Vienna. Patients or their legal guardians provided written informed consent. 
Patients' Tissue Specimens
Children between 2 and 18 years of age who underwent elective diagnostic endoscopy of the upper and/or lower GI tract at the Department of Paediatrics and Adolescent Medicine, Medical University of Vienna were randomly invited to participate. Subjects with increased risk of bleeding or perforation and patients scheduled for endoscopic interventions or undergoing non-elective endoscopy were excluded. Endoscopic biopsies from the esophagus, the stomach, the duodenal bulb, the terminal ileum, the ascending colon, and the rectum were either fixed in OCT Tissue Tek (Sakura Finetek, Staufen, Germany) and stored at 280uC until further processing for RT-PCR or snap-frozen for immunohistochemistry analysis. Tissue specimens were obtained from sites free of macroscopic mucosal pathology.
Immunohistochemistry
FceRIa in frozen sections of gastrointestinal specimens was detected with mAb 15.1 [31] . Sections were acetone-fixed, rehydrated and blocked in 2% (w/v) BSA/phosphate buffered saline (PBS). Endogenous peroxidases were quenched with 0.3% hydrogen peroxide/PBS for 15 minutes. Sections were exposed to blocking solution containing 2% horse serum for 20 minutes and incubated with mAb 15.1 or concentration-matched mouse IgG1 isotype control overnight at 4uC. Bound antibody was detected with VectastainH ABC peroxidase system (Vector-labs, Peterborough, UK) according to the manufacturere's protocol and visualized with AEC reagent (3-amino-9-ethylcarbazole; Dako, Carpinteria, CA, USA). Sections were counterstained with Papanicolaous Harris 1a stain (Merck, Darmstadt, Germany). 
Double Immunofluorescence Staining
Double immunofluorescence staining for FceRIa and the mast cell marker c-kit or the Langerhans cell marker CD1a were performed on frozen esophagus specimens. Sections were acetonefixed, incubated with 1 mg/ml sodium borohdyride (ICN Chemicals, Aurora, OH), and blocked with 5% v/v normal donkey serum (Jackson ImmunoResearch Lab Inc., West Grove, PA, USA). Sections were then exposed to mouse anti-FceRIa (Cra 1, clone AER-37, 1:100 dilution, eBioscience, San Diego, CA, USA) and goat anti-CD1a (clone N-19, 1:200 dilution, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or rabbit anti-c-kit (A4502, 1:250 dilution, Dako) overnight. CY5-conjugated donkey anti-mouse-, Dylight 549 donkey anti-goat-, and Dy549 donkey anti-rabbit-antibodies (Jackson ImmunoResearch Lab Inc., 1:200 dilution) were used as secondary antibodies. Secondary antibody controls were performed in parallel with each experiment. After they were washed, the sections were mounted with Prolong Gold anti-fade mounting media containing DAPI (Invitrogen, Grand Island, NY, USA). FceRIa/CD1a double-staining was investigated on a Zeiss AxioImager M1 wide-field fluorescent microscope with a 20x/0.8 N.A. plan-apochromat objective lens and the AxioVision software. FceRIa/c-kit double staining was investigated on a Zeiss LSM510 Meta confocal system and Zeiss LSM510 image acquisition software. The images were taken with a 20x/0.8 planapochromat objective and a 40x/1.3 oil plan-apochromat objective.
Real-time RT-PCR
Total mRNA was isolated from mucosal specimens using the GenElute TM Total RNA MiniPrep Kit (Sigma-Aldrich, St. Louis, MO, USA) and subjected to reverse transcription with the iScript TM cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) following the manufacturer's instructions. Quantification of mRNA was performed using the iQ SYBR Green Supermix (Bio-Rad) on a CFX96 Real time System (Bio-Rad). The thermal profile of the PCR reaction was: initial denaturation at 95uC for 3 minutes, followed by 30 cycles of denaturation at 95uC for 10 seconds and annealing/elongation at 63uC for 30 seconds, and a final melting curve. The following primers were used to amplify cDNA: FceRI a: forward: 59GAA ATG TGA CCT GCT GCT GA39, reverse: 59TGT GGC AGC TGG ACT ATG AG39; betaActin: forward: 59CTC TTC CAG CCT TCC TTC CT39, reverse: 59AGC ACT GTG TTG GCG TAC AG39. Primer sets for FceRIb and -c subunits and glyceraldehyde-3-phosphatedehydrogenase (GAPDH) were purchased from Qiagen (Hilden, Germany). Relative expression of FceRIa,-b and -c was calculated according to the Pfaffl method [39] as follows: DDCT = DCt(sample)-DCt(reference), where DCt(sample) is the Ct value of the gene of interest normalized to the endogenous housekeeping genes GAPDH and beta-Actin and DCt(reference) is the sample with the lowest DCt value. cDNA from palatine tonsils was used as positive control and included in each experiment as inter-run calibrator.
Total Serum IgE Measurement
Serum samples for IgE measurement were collected at the time of endoscopy.
Total IgE was determined using the Phadia ImmunoCAPH solid phase immunoassay (Pharmacia Diagnostics, Uppsala, Sweden). Total serum IgE levels are given in kU/l. For some analyses, patients were subgrouped into elevated-and normal-IgE-patients. Expected normal ranges for this assay are 40 kU/l for age , one year, 100 kU/l for the 2 nd year of life, 150 kU/l for the 3 rd year of life, 190 kU/l for the 4 th and 5 th years of life, 150 kU/l for the 6 th year of life, 120 kU/l for the 7 th to the 16 th year of life, and 100 kU/l for patients older than 16 years.
Statistical Analysis
Statistical analyses were carried out with SPSS software (Version 17.0 SPSS Inc., Chicago, IL, USA). Differences in tissue mRNA levels between groups were tested for statistical significance with two-sided Kruskal-Wallis-H-test and two-sided MannWhitney U-test with Bonferroni-Holm correction. Correlations of data with serum IgE were determined using Spearman rank correlation test. For certain analyses, total serum IgE values were transformed into z-units to adjust for age dependent normal values as published by Kjellman et al. [33] . P-values ,0.05 were considered statistically significant.
